529 filings
Page 19 of 27
8-K
5b3rvvq7
31 Mar 17
Heat Biologics Reports Fiscal Year 2016 Financial Results
12:00am
424B2
huldt8mdyenly5
24 Mar 17
Prospectus for primary offering
12:00am
8-K
t6w t0pd0ij1a
24 Mar 17
Heat Biologics Announces Proposed Public Offering of Common Stock
12:00am
8-K
5b8az1
23 Mar 17
Results of Operations and Financial Condition
12:00am
424B5
v9hlu n11lusazra4cuu
23 Mar 17
Prospectus supplement for primary offering
12:00am
8-K
mv7a4zl
21 Mar 17
Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
12:00am
8-K
qtisuhj kk52
16 Mar 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
7f05vl5leqjzmqsd2ib
13 Mar 17
Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2
12:00am
8-K
rxbuv6w7v4zxt awk
8 Mar 17
Heat Biologics Announces Agreement to Acquire Pelican Therapeutics
12:00am
8-K
xso1g aipm00fri4k
3 Feb 17
Other Events
12:00am
424B5
dq8 unwgbevmzzokv5o
3 Feb 17
Prospectus supplement for primary offering
12:00am
8-K
955qbhntn2m4nfq4qsxz
6 Jan 17
Regulation FD Disclosure
12:00am
EFFECT
j7wtp4a1sutf tv
5 Jan 17
Notice of effectiveness
12:00am
8-K
9oc8k
4 Jan 17
Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer
12:00am
CORRESP
q1265oc3mbcyjmqwl7m
3 Jan 17
Correspondence with SEC
12:00am
CT ORDER
o4rzq4hu
3 Jan 17
Confidential treatment order
12:00am
CORRESP
169lcig2m17iygoggc
21 Dec 16
Correspondence with SEC
12:00am
S-3/A
66y6wkkhkhssa
21 Dec 16
Shelf registration (amended)
12:00am
UPLOAD
o5s zyyml
14 Dec 16
Letter from SEC
12:00am
8-K
sim7i62
9 Dec 16
Termination of a Material Definitive Agreement
12:00am